Demand for Biological Implants and Impact of COVID-19……..



Global biological implant market is anticipated to reach USD 9.8 billion by 2024, according to a new report by Grand View Research, Inc. Biological implant market is driven by rise in adoption of grafts and organ substitutes for reconstructive surgeries for various clinical applications such as cardiovascular, orthopedic and other soft tissue repair. The main challenge associated with the use of these products is to incorporate such a material that can specifically adapt to the biology of the surrounding environment in order to accelerate regeneration and repair. To overcome this challenge, research endeavors are carried out in order to develop such devices from biological source thus affecting industrial growth in the coming years.
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.
Modification in the process of composite grafting is expected to play a crucial role in tackling reimplantation of amputated fingertips by bringing development in the overall process of grafting. Moreover, rising competition amongst key participants operating in this market is one of the high impact rendering factors to accelerate the growth.
"Biological implants market is driven by development in composite grafting coupled with rising advancements in tissue engineering"
The global biological implants market was valued at USD 5,070.8 million in 2015 and is expected to exhibit a growth rate of 7.6% over the forecast period. With technological breakthroughs in the fields of regenerative medicine and tissue engineering, the market for biological implants is expected to witness substantial demand and sales over the forecast period.
Emergence of biomaterials to perform reconstructive procedures that are compatible and less cumbersome will considerably increase the revenue generation and drive progress up to 2024. Substantial advancements have been made in precise implant surgical procedures for more aesthetic and predictable outcomes. Aforementioned developments and advancements in implant and tissue regeneration collectively bolsters growth for these products.
To Request Sample Copy of this report, click the link:
Further key findings from the report suggest:
·         Depending upon the source or donor of grafts, products offered can be categorized into autograft, allografts, and xenografts. Xenografts dominated the revenue share in 2015 with a revenue share of over 50%. However, allografts are expected to witness the fastest growth owing to the fact that they are derived from same species and produce considerably less chances of foreign immune reaction, thereby influencing adoption rate.
·         Biological implants serve various application domains which include cardiovascular, orthopedic, and other soft tissue implants. Soft tissue products accounted for the largest share in 2015 as a result of higher usage of the products in the field of dentistry. Even though cardiovascular implants accounted for lowest penetration in the current scenario, demand for cardiovascular stents and valves obtained from biological source is expected to expand, consequently boosting revenue generation from this segment.
·         Amongst surgical and injectable mode of administration, surgical mode is estimated to hold the larger share, as a consequence of availability of several products administered via this route. Introduction of minimally invasive techniques for surgical incorporation of grafts is also one of the significant factors propelling growth in this segment.
·         North America dominated the market with a revenue share of 50% due to widespread presence of participants coupled with high aesthetic and healthcare awareness levels amongst the population in this region.
·         Asia Pacific is estimated to exhibit the fastest growth in the coming years due to presence of the target population and rapidly improving health care infrastructure which is attributed to drive the demand for tissue engineered products and biological implants.
·         Major players operating in this industry include Medtronic, NuVasive, Inc, Stryker Corporation, Conmed Corporation, CryoLife, Edwards LifeSciences Corporation, Acelity, Integra LifeSciences Corporation, Allergan Plc, RTI Surgical, IOP Ophthalmics, Organogenesis Inc, BioPolymer GmbH & Co. KG, Osiris Therapeutics, Baxter International, Vericel, Aplhatec Spine Inc, Maxigen Biotech Inc, Auto Tissue Berlin GmbH, MiMedx Group, Inc., Biotissue Technologies,
·         These players are undertaking different business strategies to boost their respective penetration and enhance market presence. These strategies include novel product developments and geographic expansion by involving in collaborative activities in order to grab the larger share of revenue. For instance, in April 2016, Stryker Corporation acquired Stanmore Implants Worldwide Limited which is expected to enable the company to provide differentiated technologies to orthopedic oncology surgeons, thus propelling growth over the forecast period.
Moreover, companies are playing pivotal role in addressing the challenge of foreign body rejection associated with synthetic devices by development of biologically derived reconstructive solutions. Novel product development will continue to rise globally, encouraging companies to proactively optimize their portfolios in this vertical, consequently influencing revenue generation.
Development in the regenerative medicine sector which includes a variety of therapeutic approaches such as utilization of bio based materials and biologics for targeting the root cause of an ailment has sparked a new trend leading to increasing adoption of these products is one of the crucial factors propelling market growth over the forecast period. Development of soft tissue grafts for a number of complex procedures such as abdominal wall reconstruction, thoracic reconstruction, breast reconstruction among others owing to lower contamination rates of bioprosthetic mesh materials along with stable vascularization even at infected wound sites and lower visceral repair site adhesions are key reasons due to which they are used as compared to prosthetic mesh materials.
High manufacturing cost and hesitant uptake due to adverse events are anticipated to derail the projected progress to a certain extent.
“Xenografts accounted for the largest share of the product segment in 2015"
Xenografts accounted for the largest share in 2015 owing to advancements in the field of vascular engineering and tissue engineering for the treatment of diseases with the use of scaffold that is a structurally intact xenogeneic vessel, such as a pig aorta. Availability and ease of procurement of the xenogeneic grafts without the issue of donor site morbidity is anticipated to impact revenue generation significantly.
Allografts are expected to experience the fastest growth in the coming years. Superior aesthetic results obtained with their use is anticipated to augment the sale and demand in this segment.
Have any Query? Ask our Experts:
"Rising incidence of cardiovascular disorders are expected to propel the cardiovascular implants segment growth"
Various applications of these products includes orthopedic, cardiovascular and other soft tissue implants. Soft tissue implants held the majority share of over 44% owing to the availability of wide range of products falling in this category.
Although, cardiovascular implants are observed to have low penetration in 2015, it is expected to witness fastest growth in the coming years. Rising incidence of cholesterol abnormalities and cardiovascular disorders is anticipated to positively reinforce this segment’s potential in the coming years. Availability of various cardiac tissues in the market in the form of allograft valves, heterograft valves that are obtained from porcine heart & bovine pericardial valves, and a stentless valve which can be trimmed according to the requirement is attributed to the projected progress in this segment.
"Surgical biological implants are most adopted route of administration"
Grand View Research has segmented biological implant market on the basis of product, application, mode of administration:
Devices Outlook, by Product (Revenue, USD Million, 2013 - 2024)
·         Autografts
·         Allografts
·         Xenografts
Outlook, by Application (Revenue, USD Million, 2013 - 2024)
·         Cardiovascular Implants
·         Orthopedic Implants
·         Other Soft Tissue Implants
Devices Outlook, by Mode of Administration (Revenue, USD Million, 2013 - 2024)
·         Surgical
·         Injectable
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.




Comments

Popular posts from this blog

Foot Orthotic Insoles Market 2026: What Will Be Changes In Investment Ratio With Opportunity Analysis?? |Grand View Research, Inc.

A Look into Smokehouse Industry……Deep Analysis…..

A Look into Shapewear Industry……Deep Analysis…..